20,128 Days of Data

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CHICAGO, Oct. 4, 2019 /PRNewswire/ — Dr. Steven Fox and Healthcare Analyst Joseph Person recently presented The Power and Value of Your Data to a standing room only audience at the Home Care Association of America annual meeting in Tucson, Arizona. The presentation detailed the seismic shift in medicine and healthcare from trust to doubt and prerogative to accountability. The growth and inevitable shift to value based payment and Medicare Advantage programs was addressed. The importance of real-time patient generated health data and telehealth were validated by 20,128 days of patient data through the Home Care MetricsSMprogram.

              The Home Care MetricsSMStudy
                 N=37
                 Mean Age: 86.3 (65-104 years)
                 Number of Chronic Conditions 3.8

Medicare    

HCM

           30 Day Readmission Rate      

13.9%

0.25%

           30 Day Fall Rate

36.9%

0.25%

           30 Day ER Visits Rate            

18.2%

0.93%

Home Care MetricsSM is a telehealth platform use by complex chronically ill patients to prevent and avoid hospitalizations and emergency room care.

Contact:
Steven C. Fox D.O., Home Care MetricsSM
Phone: 312-953-5202
Email: 224226@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/20-128-days-of-data-300931064.html

SOURCE Home Care Metrics

Staff

Recent Posts

EssilorLuxottica and Meta to launch Oakley Meta, creating a new category of Performance AI glasses for athletes and fans alike

EssilorLuxottica and Meta to launch Oakley Meta, creating a new category of Performance AI glasses…

2 hours ago

INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time

SARASOTA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility”…

2 hours ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC)…

2 hours ago

Safety Shot Provides Update on Expected Closing of Yerbaé Brands Corp. Acquisition

SCOTTSDALE, AZ, June 20, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot”…

2 hours ago

Emergent BioSolutions Announces Addition to Russell 3000® Index

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced…

2 hours ago